EIGHTEEN asthmatic children were challenged with ultrasoically nebulized cold distilled water (UNCDW). Blood gas composition was monitored transcutaneously (tcpO₂ and tcpCO₂) during and after the challenge. Assuming as basal the response to this UNCDW test, nine children (Group A) were then chosen at random to inhale cromoglycate by aerosol delivery for 8 days. Nine children (Group B), acting as a control, inhaled saline for 8 days. At the end of this therapy, each child repeated the UNCDW test. Statistical analysis with t-test for paired data was used to compare the results of each child to both tests. Mean basal tcpO₂ and tcpCO₂ were all within the expected normal range. In all children, both mean tcpO₂ and tcpCO₂ were reduced during and after UNCDW inhalation. Mean tcpCO₂ values during the challenge were significantly (p < 0.001) lower than the corresponding steady state 2 min after the UNCDW challenge, with a mean drop of -7% (2.1 S.D.). Mean tcpO₂ values remained significantly decreased (p < 0.001) from the fifth minute of the UNCDW challenge to the end of the observation period, with a mean drop of -20% (15.5 S.D.). After treatment with cromoglycate (Group A), the mean tcpCO₂ values during UNCDW did not change significantly from those of steady state conditions: -0.8% (0.5 S.D.); whereas mean tcpO₂ values decreased by -4% (4.9 S.D.). The control children treated with saline (Group B) showed mean tcpCO₂ and tcpO₂ values which were significantly different (p < 0.001) from those of the steady state conditions: mean drop of tcpCO₂, -6% (4.2 S.D.); mean drop of tcpO₂, -20% (4.7 S.D.). In conclusion, it emerges that UNCDW induces nonspecific broncho-constriction in asthmatic children with a typical drop of tcpCO₂ (hyper-reactivity) and reduces dramatically the drop of tcpO₂ time course (hyper-responsivity) during and after the UNCDW test.

Key words: Asthma, Children, Cromoglycate, O₂ and CO₂ time course, Ultrasonic nebulized distilled water

Effect of cromoglycate on gas changes, during bronchial challenge by UNCDW in children with asthma

L. Mappa, S. Bavaro, G. Moramarco, D. Torio, D. Falciaore, G. Ciccarone, L. Ciciomessere and N. Rigillo

Istituto di Pediatria Clinica e Sociale, University of Bari Policlinico, Piazza G. Cesare, 70124 Bari, Italy

CA Corresponding Author

Introduction

Experience over the past 20 years has demonstrated the ability of cromoglycate to function as a mast cell stabilizer or inhibitor. Cromoglycate can be so considered among the anti-inflammatory drugs for asthma because it reduces bronchial hyper-reactivity and decreases airway hyper-responsiveness.

This study was designed to obtain further information on the effect of cromoglycate on the time courses of transcutaneous oxygen and carbon dioxide pressure (tcpO₂ and tcpCO₂), during bronchial challenge by ultrasonic nebulized 'cold' distilled water (UNCDW) in children with asthma. The possibility of performing continuous non-invasive monitoring of gas composition has been achieved by means of electrodes for transcutaneous PO₂ and PCO₂ monitoring.

This technique provides an accurate way of monitoring gas exchange changes during and after bronchial challenge.

The bronchial challenge used is ultrasonically nebulized cold distilled water (UNCDW), which induces bronchoconstriction in children with asthma. The method is simple and reproducible, and is characterized by a high degree of specificity.

Materials and Methods

A placebo controlled study was undertaken on 18 asthmatic children (eight males, ten females) aged 3 to 12 years, with bronchial hyper-reactivity. At the time of the investigation, all children were free of symptoms and had not received any drug during the
previous 8 days. Before submitting children to the study, informed consent was obtained from their parents.

Transcutaneous oxygen pressure (tcpO₂) and carbon dioxide (tcpCO₂) were monitored by the Gasthmatic system, after calibration, by placing the heated monoelectrode (44°C) on the upper chest of each child and allowing a stabilization period of 15–20 min. Baseline data were collected when the tcpO₂ and tcpCO₂ had reached a steady state level and the children were lying quietly without body movements.

The children were then given the UNCDW test: ultrasonic nebulizer De Vilbiss Ultra-neb 99 at 5 ml/min flow for 7 min was used. Cold distilled water was obtained by freezing it to around 0°C, and using it just at the time of testing. The tcpO₂ and tcpCO₂ values were recorded in the 5 min before the challenge, throughout the challenge procedures, and for 30 min following the end of nebulization.

For statistical purposes, comparisons were made between the mean values at the steady state level before nebulization and those measured during 0–5 and 15–30 min after nebulization. A tcpO₂ drop of over 15% below the baseline was taken as a positive response.

Assuming the response to UNCDW test as basal, nine children (Group A) were then chosen at random to inhale cromoglicate by aerosol delivery for 8 days (20 mg three times/day). Nine children (Group B) acted as placebo control, and inhaled saline (2 ml three times/day) for 8 days.

At the end of this therapy, each child repeated the UNCDW test. Statistical analysis with t-test for paired data was used to compare the results for each child for both tests.

Results

Basal values: The mean basal values for tcpO₂ and tcpCO₂ were all within the expected normal range. There were no significant differences in these baseline variables between the two groups of subjects.

Response to UNCDW: In all children, both mean tcpO₂ and tcpCO₂ were reduced during and after UNCDW inhalation. TcpCO₂ decreased immediately after the start of UNCDW exposure and the decrease was maximal around the third min of the challenge. The tcpCO₂ level started to pick up again immediately after the end of the exposure and the recovery was almost complete 5 min after the UNCDW test, with tcpCO₂ remaining more or less steady from that point onwards (Fig. 1).

The tcpO₂ time course was quite different, the decrease beginning at the fourth min of UNCDW inhalation and reaching the lowest value 4 min after the end of exposure (Fig. 2). Mean tcpCO₂ values during the challenge were significantly lower than the corresponding baseline (p < 0.001) 2 min after the UNCDW challenge, with a mean drop of −7% (2.1 S.D.). Mean tcpO₂ values remained significantly decreased (p < 0.001) from the fifth min of the UNCDW challenge to the end of the observation period, with a mean drop of −20% (15.5 S.D.).

After treatment with cromoglicate in children of Group A, the mean tcpCO₂ values during UNCDW were not significantly different from those of steady state (−0.8% (0.5 S.D.)), whereas mean tcpO₂ values decreased by −4% (4.9 S.D.).

The children treated with saline (Group B) showed mean tcpCO₂ and tcpO₂ values which were significantly different (p < 0.001) from those of the steady state (mean drop of tcpCO₂ -6% (4.2 S.D.); mean drop of tcpO₂ −20% (4.7 S.D.)).

Comparisons made between tcpCO₂/O₂ data for each child of Group A to both tests (before and after therapy), showed a statistically significant difference (p < 0.001). Between data for each child of Group B, there were no statistically significant differences to both tests.

Discussion

The possibility of monitoring blood gases with a non-invasive method (Gasthmatic) and the evalua-
Effect of cromoglycate on gas changes

tion in real time of their trends of variation, allowed us to identify the different bronchial structures involved in the hyper-reactive response. Furthermore, only in asthmatics does the bronchial challenge induce an appreciable degree of hypoxia with a later onset, shifted maximum effect, and longer duration, indicative of a mismatched ventilation/perfusion ratio.

We could verify that, unlike normal adult subjects, asthmatics (also free of symptoms), had unusual time courses for tcpO2 and tcpCO2 during UNCDW, namely: (1) the first phase in which tcpCO2 decreased immediately after the start of UNCDW exposure; and (2) the second phase in which tcpO2 decreased at about the fourth min of inhalation, reaching the lowest value four min after the end of exposure.

It is reasonable to suggest that the initial drop of tcpCO2 is linked to the response of the bronchial mucosa, the first target of the challenge. This allows us to evaluate the behaviour of the bronchial epithelium which is the seat of inflammation (hyper-reactivity).

The phase following this is the contraction of the smooth muscle, leading to bronchospasm, and then to the drop in tcpO2 (hyper-responsivity).

A further demonstration of this behaviour is that the previous administration of a beta-2 agonist drug 10 min before the challenge was shown to prevent the occurrence of a hypoxic response to the fog (effect on the bronchial hyper-responsivity), while the hypocapnic response remained unchanged. The treatment with anti-inflammatory drugs showed (in adults) the gradual normalization of the time courses of pCO2 (effect on bronchial hyper-reactivity). In this study, we obtained the same time courses of blood gases during the UNCDW test in children as had been observed in adults; on the other hand, after treatment with cromoglycate (Group A), a normalization of the time course for pCO2 occurred and only a small decrease of tcpO2 (not above 10% from baseline) was observed.

In conclusion, it emerges that: UNCDW induces non-specific bronchoconstriction in asthmatic children, with a similar time course of blood gases to that of adults; the treatment with cromoglycate normalizes the time course of pCO2 (hyper-reactivity) and reduces dramatically the drop in the pO2 time course (hyper-responsivity) during and after the UNCDW test.

References
Submit your manuscripts at http://www.hindawi.com